Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth

Krystal Biotech (KRYS) is anticipated to report Q3 2025 earnings of $1.12 per share, representing a 23.1% year-over-year increase, with revenues projected at $91.5 million, up 9.1%. While consensus EPS estimates have been revised 15.22% higher over the last 30 days, the company's negative Zacks Earnings ESP of -1.18% combined with a Zacks Rank #3 (Hold) makes it difficult to conclusively predict an earnings beat, despite a history of surpassing consensus EPS in three of the last four quarters.

Analysis

Krystal Biotech (KRYS) is anticipated to report Q3 2025 earnings of $1.12 per share, representing a 23.1% year-over-year increase, with revenues projected at $91.5 million, up 9.1%. Notably, the consensus EPS estimate has seen a significant 15.22% upward revision over the past 30 days, indicating improved analyst expectations leading into the report.

Despite these positive revisions, Krystal Biotech's Zacks Earnings ESP stands at -1.18%, suggesting the Most Accurate Estimate is now lower than the consensus, implying recent bearish sentiment among analysts. Coupled with a Zacks Rank #3 (Hold), this combination makes a definitive prediction of an earnings beat challenging, as negative ESP readings are not reliable indicators of a miss.

Historically, KRYS has demonstrated a strong track record, beating consensus EPS estimates in three of the last four quarters, including a substantial 19.44% beat in the prior quarter. However, the current negative Earnings ESP leads to a conclusion that Krystal Biotech does not appear to be a compelling earnings-beat candidate for the upcoming report.

Key Decisions for Investors

• Investors should closely monitor Krystal Biotech's actual Q3 2025 EPS and revenue against consensus estimates of $1.12 and $91.5 million, respectively, given the mixed predictive signals.
• Evaluate management's commentary on business conditions during the earnings call, as this will be critical for understanding future outlook and the sustainability of any post-earnings price action.
• Exercise caution regarding pre-earnings positioning based solely on an earnings beat, considering the negative Zacks Earnings ESP of -1.18% and the assessment that KRYS is not a compelling earnings-beat candidate.
• Factor in broader market dynamics and company-specific catalysts beyond just the earnings numbers, as these can significantly influence stock performance regardless of a beat or miss.